Endpoints for clinical trials on treatment of hepatitis C

Review

Hellan Kang et al. J Hepatol. 2006 Oct.

. 2006 Oct;45(4):473-5.

doi: 10.1016/j.jhep.2006.07.007. Epub 2006 Jul 25.

No abstract available

Comment on

Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Orlent H, et al. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015. Epub 2006 Jun 30. J Hepatol. 2006. PMID: 16905220 Clinical Trial.

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.
Pawlotsky JM, McHutchison JG. Pawlotsky JM, et al. Hepatology. 2004 Feb;39(2):554-67. doi: 10.1002/hep.20065. Hepatology. 2004. PMID: 14768012 Review. No abstract available.
Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.
Tang J, Kaslow RA. Tang J, et al. Pharmacogenomics J. 2004;4(3):171-4. doi: 10.1038/sj.tpj.6500246. Pharmacogenomics J. 2004. PMID: 15069460 Review. No abstract available.
Novel hepatitis C drugs in current trials.
Kronenberger B, Welsch C, Forestier N, Zeuzem S. Kronenberger B, et al. Clin Liver Dis. 2008 Aug;12(3):529-55, viii. doi: 10.1016/j.cld.2008.03.001. Clin Liver Dis. 2008. PMID: 18625427 Review.
Future directions in therapy for chronic hepatitis C.
Jensen DM, Ascione A. Jensen DM, et al. Antivir Ther. 2008;13 Suppl 1:31-6. Antivir Ther. 2008. PMID: 18432161 Review.
Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C.
O'Brien C. O'Brien C. J Viral Hepat. 2006 May;13 Suppl 1:6-14. doi: 10.1111/j.1365-2893.2006.00757.x. J Viral Hepat. 2006. PMID: 16630042 Review.